Ultime notizie per XWELL (NASDAQ:XWEL) Azioni

XWELL

XWELL Inc is a health and wellness holding company. It is an airport retailer of spa services through XpresSpa locations, offering travelers premium spa services, including massage, nail, and skincare, as well as spa and travel products. It operates four reportable operating segments: XpresSpa. XpresTest, Naples Wax Center and Treat. XpresSpa provides travelers premium spa services, including massage, nail and skin care, as well as spa and travel products.. Treat is a travel health and wellness brand that offers in-airport spa. XpresTest provides COVID-19 screening and diagnostic testing in partnership with the CDC. Naples Wax Center operates three high-performing locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products.

XWELL Inc

Fiscal 2025 Outlook
The Company's outlook for 2025 was updated as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(as of November 8, 2024)</td>
<td colspan="1" rowspan="1">Updated Fiscal 2025 Guidance</td>
<td colspan="1" rowspan="1">Previous Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Sales</td>
<td colspan="1" rowspan="1">$200 million to $210 million</td>
<td colspan="1" rowspan="1">$200 million to $210 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">23% to 24% of sales</td>
<td colspan="1" rowspan="1">22% to 23% of sales</td>
</tr>
<tr>
<td colspan="1" rowspan="1">SG&amp;A expense (including amortization)(1)</td>
<td colspan="1" rowspan="1">17.0% to 18.0% of sales</td>
<td colspan="1" rowspan="1">16.5% to 17.5% of sales</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA(2)</td>
<td colspan="1" rowspan="1">$18.0 million to $21.0 million</td>
<td colspan="1" rowspan="1">$16.5 million to $19.5 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective Tax Rate</td>
<td colspan="1" rowspan="1">20% to 22%</td>
<td colspan="1" rowspan="1">20% to 22%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital Expenditures</td>
<td colspan="1" rowspan="1">$13.0 million to $18.0 million</td>
<td colspan="1" rowspan="1">$10.0 million to $15.0 million</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Includes approximately $6.5 million to $7.5 million of BN supplemental performance bonus, equity-based compensation, and ERP conversion costs included in SG&amp;A expense.</td>
</tr>
</tbody>
</table>
</figure>

Earnings

News

Guidance

Graham Reaffirms 2025 Net Sales Outlook Of $200M-$210M Vs. $205.40M Est.; Raises Gross Margin Guidance To 23%-24% From 22%-23% And Adj. EBITDA To $18M-$21M From $16.5M-$19.5M

Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $0.60 by 100 percent. The company reported quarterly sales of $1.69 billion which beat the analyst consensus estimate of $1.59 billion by 6.34 percent. This is a 31.73 percent increase over sales of $1.28 billion the same period last year.

Earnings Beats

Embraer-Empresa Brasileira De Aeronautica

Embraer Q3 2024 Adj EPS $1.20 Beats $0.60 Estimate

Keybanc analyst Scott Schoenhaus upgrades Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from Sector Weight to Overweight and announces $70 price target.

Upgrades

Price Target

Analyst Ratings

DOCS

Keybanc Upgrades Doximity to Overweight, Announces $70 Price Target

DCBO

Docebo Raises FY24 Outlook: Sees Total Revenue Growth Of Approximately 19.5% (Prior View: 18.0%-19.0%), Adjusted EBITDA As A Percentage Of Total Revenue Of Approximately 15.5%

Advanced Drainage Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>) reported quarterly earnings of $1.70 per share which missed the analyst consensus estimate of $1.90 by 10.53 percent. This is a 0.58 percent decrease over earnings of $1.71 per share from the same period last year. The company reported quarterly sales of $782.61 million which missed the analyst consensus estimate of $822.35 million by 4.83 percent. This is a 0.31 percent increase over sales of $780.22 million the same period last year.

Earnings Misses

Advanced Drainage Systems Q2 2025 Adj EPS $1.70 Misses $1.90 Estimate, Sales $782.61M Miss $822.35M Estimate

Management expects subscription revenue to grow about two percentage points higher than overall company revenue while professional services revenue to be down sequentially from Q3.

Docebo Sees Q4 Revenues Of $56M-$56.2M Vs. $56.02M Estimate; Adjusted EBITDA Margin Of 16.5%-16.7%

Raymond James analyst Justin Jenkins downgrades EnLink Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENLC#NYSE">ENLC</a>) from Outperform to Market Perform.

Downgrades

ENLC

Raymond James Downgrades EnLink Midstream to Market Perform

Full-year 2024 Adjusted EBITDA Guidance Remains Unchanged At A Range Of $220 Million To $240 Million.

FTRE

Fortrea Narrows FY24 Revenue Guidance From $2.70B - $2.75B To $2.70B - $2.725B, Est $2.697B

2024 Financial Guidance
Management reiterates its full year 2024 guidance:
<ul>
<li>Anticipated Total Net Revenues expected to be between $87 million and $95 million;</li>
<li>Anticipated Operating Expenses expected to remain between $115 million and $120 million;</li>
<li>Anticipated Total Annual Cash Investment expected to remain between $15 million and $20 million; and</li>
<li>Cash and Cash Equivalents anticipated to continue to support operations as currently planned into 2027.</li>
</ul>

Biotech

Health Care

General

YMAB

Y-mAbs Anticipates 2024 Total Net Revenues Of $87M-$95M Vs. Consensus Of $91.67M

Atmus Filtration Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATMU#NYSE">ATMU</a>) raises FY2024 Adj EPS guidance from $2.15-2.40 to $2.35-2.50 vs $2.20 analyst estimate. Raises FY2024 sales outlook from $1.63 billion-1.68 billion to $1.65 billion-1.68 billion vs $1.66 billion estimate.

ATMU

Atmus Filtration Techs Raises FY2024 Adj EPS Guidance from $2.15-2.40 to $2.35-$2.50 vs $2.20 Est; Raises FY2024 Sales Guidance from $1.63B-$1.68B to $1.65B-$1.68B vs $1.66B Est

Atmus Filtration Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATMU#NYSE">ATMU</a>) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.49 by 24.49 percent. This is a 17.31 percent increase over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $403.70 million which beat the analyst consensus estimate of $403.41 million by 0.07 percent. This is a 1.89 percent increase over sales of $396.20 million the same period last year.

Atmus Filtration Techs Q3 Adj $0.61 Beats $0.49 Estimate, Sales $403.70M Beat $403.41M Estimate

Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 11.11 percent increase over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $18.46 million which missed the analyst consensus estimate of $23.26 million by 20.64 percent. This is a 9.74 percent decrease over sales of $20.45 million the same period last year.

Y-mAbs Therapeutics Q3 2024 GAAP EPS $(0.16), Inline, Sales $18.46M Miss $23.26M Estimate

On Thursday, November 8th, U.S. markets ended mixed after the Federal Reserve cut interest rates by 25 basis points, citing an eased job market and progress toward the 2% inflation target. Optimism over President-elect Donald Trump&#8217;s return lifted the S&amp;P 500 and Nasdaq to record highs, with global markets rallying in response.
Financials led declines among S&amp;P sectors, reversing strong gains from the previous session as bank stocks fell sharply.
The Federal Reserve cut rates by 0.25 points to a 4.5%-4.75% range, slowing the pace of easing from September&#8217;s 0.5% cut.
In economic data, U.S. initial jobless claims rose to 221,000 in late October, while Q3 nonfarm productivity increased by 2.2% and unit labor costs grew by 1.9%. Wholesale inventories fell 0.2% in September, and natural gas stocks climbed by 69 billion cubic feet to 3.932 trillion.
The Dow Jones Industrial Average was flat and closed at 43,729.34, the S&amp;P 500 rose 0.74% to 5,973.10, and the Nasdaq Composite soared 1.51% to finish at 19,269.46.
Asia Markets Today
<ul>
<li>On Friday, Japan&#8217;s Nikkei 225 gained 0.19% and ended the session at 39,468.50, led by gains in the Textile, Shipbuilding and Steel sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 rose 0.84% and ended the day at 8,295.10, led by gains in the Gold, IT, and Consumer Discretionary sectors.     </li>
<li>India&#8217;s Nifty 50 traded lower by 0.21% at 24,148.20, and Nifty 500 was down 0.70% at 22,645.65.</li>
<li>China&#8217;s Shanghai Composite slid 0.53% to close at 3,452.30, and the Shenzhen CSI 300 declined 1.00%, finishing the day at 4,104.05.</li>
<li>Hong Kong&#8217;s Hang Seng fell 1.7% and closed the session at 20,728.19.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 index was down 1.09%.</li>
<li>Germany&#8217;s DAX declined 0.99%.</li>
<li>France&#8217;s CAC fell 1.13%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 0.72%.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 1.64% at $71.19/bbl, and Brent was down 1.35% at $74.62/bbl.</li>
<li>Oil prices edged lower as Hurricane Rafael&#8217;s impact on U.S. output eased and markets assessed Trump&#8217;s potential policies on global supply.</li>
<li>Natural Gas gained 0.63% to $2.710.</li>
<li>Gold was trading lower by 0.49% at $2,692.00, Silver fell 1.11% to $31.503, and Copper slipped 2.30% to $4.3290.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures slipped 0.04%, S&amp;P 500 futures were down 0.03%, and Nasdaq 100 futures fell 0.14%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. dollar index declined 0.02% to 104.49, the USD/JPY was down 0.39% to 152.37, and the USD/AUD rose 0.68% to 1.5072.</li>
<li>The U.S. dollar edged higher this week, buoyed by &#8220;Trump trades&#8221; but tempered by policy uncertainty. The yen rose, and the Australian dollar logged solid weekly gains.</li>
</ul>
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe, Crude Oil, Gold And Dollar Cool Off - Global Markets Today While US Slept

STRW

Strawberry Fields REIT Registers Q3 AFFO Of $14.3M, Higher Than $11.5M YoY; Company Declared Cash Dividend Of $0.14 Per Share That Will Be Paid On December 30

Phil Eyler to Remain as an Advisor to Gentherm through June 30, 2025.

Management

THRM

Gentherm Plans CEO Succession In 2025; Bill Presley To Become President And CEO, And Board Director, As Of January 1, 2025

JMP Securities analyst Andrew Boone downgrades Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) from Market Outperform to Market Perform.

NRDY

JMP Securities Downgrades Nerdy to Market Perform

Graham (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHM#NYSE">GHM</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.14 by 121.43 percent. This is a 342.86 percent increase over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $53.563 million which beat the analyst consensus estimate of $49.700 million by 7.77 percent. This is a 18.83 percent increase over sales of $45.076 million the same period last year.

Graham Q2 2025 Adj. EPS $0.31 Beats $0.14 Estimate, Sales $53.563M Beat $49.700M Estimate

HSBC analyst Daniel Yang downgrades Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) from Buy to Hold and lowers the price target from $154 to $81.

ENPH

HSBC Downgrades Enphase Energy to Hold, Lowers Price Target to $81

Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) reported quarterly earnings of $0.23 per share which missed the analyst consensus estimate of $0.25 by 8 percent. The company reported quarterly sales of $674.90 million which met the analyst consensus estimate. This is a 13.07 percent decrease over sales of $776.40 million the same period last year.

Fortrea Holdings Q3 2024 Adj EPS $0.23 Misses $0.25 Estimate, Sales $674.90M Inline

Guggenheim analyst Seamus Fernandez initiates coverage on Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announces Price Target of $33.

Initiation

CDTX

Guggenheim Initiates Coverage On Cidara Therapeutics with Buy Rating, Announces Price Target of $33

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
XWELL (NASDAQ:<a href="https://investorplace.com/stock-quotes/xwel-stock-quote/">XWEL</a>) just reported results for the fourth quarter of 2023.<ul><li>XWELL reported earnings per share of -$1.57. This was below the analyst estimate for EPS of -82 cents.</li><li>The company reported revenue of $7.40 million.</li><li>This was 15.59% worse than the analyst estimate for revenue of $8.77 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/xwel-stock-earnings-xwell-for-q4-of-2023/">XWEL Stock Earnings: XWELL Misses EPS, Misses Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XWEL Stock Earnings: XWELL Misses EPS, Misses Revenue for Q4 2023

XWELL reports Q1 results

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
XWELL (NASDAQ:<a href="https://investorplace.com/stock-quotes/xwel-stock-quote/">XWEL</a>) just reported results for the first quarter of 2024.<ul><li>XWELL reported earnings per share of -60 cents.</li><li>The company reported revenue of $8.73 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/xwel-stock-earnings-xwell-for-q1-of-2024/">XWEL Stock Earnings: XWELL Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XWEL Stock Earnings: XWELL Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into this morning and we have all of the hottest news worth checking out on Thursday!



Moving stocks this morning are an acquisition deal, a clinical trial launch, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Chuy&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/chuy-stock-quote/">CHUY</a>) stock is rocketing more than 46% on a <a href="https://www.nasdaq.com/press-release/darden-restaurants-acquire-chuys-holdings-inc-approximately-605-million-transaction">$605 million acquisition deal</a>.</li>



<li>Onconetix (NASDAQ:<a href="https://investorplace.com/stock-quotes/onco-stock-quote/">ONCO</a>) shares are soaring over 43% alongside heavy pre-market trading.</li>



<li>Apollomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/aplm-stock-quote/">APLM</a>) stock is surging more than 25% with strong early morning trading.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) shares are rising over 23% as it <a href="https://www.nasdaq.com/press-release/bionomics-initiates-affirm-1-phase-3-clinical-trial-bnc210-social-anxiety-disorder">kicks off a Phase 3 clinical trial</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) stock is increasing more than 18% with strong pre-market trading.</li>



<li>ZimVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/zimv-stock-quote/">ZIMV</a>) shares are heading over 13% higher without any clear news on Thursday morning.</li>



<li>SAI.TECH Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/sai-stock-quote/">SAI</a>) stock is gaining more than 12% on a <a href="https://www.globenewswire.com/news-release/2024/07/18/2914992/0/en/SAI-TECH-Global-Corporation-Announces-Share-Repurchase-Program.html">share repurchase program</a>.</li>



<li>MultiMetaVerse (NASDAQ:<a href="https://investorplace.com/stock-quotes/mmv-stock-quote/">MMV</a>) shares are climbing over 11% as it continues a recent rally.</li>



<li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) stock is jumping more than 10% despite a lack of news today.</li>



<li>XWELL (NASDAQ:<a href="https://investorplace.com/stock-quotes/xwel-stock-quote/">XWEL</a>) shares are up over 10% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Leslies (NASDAQ:<a href="https://investorplace.com/stock-quotes/lesl-stock-quote/">LESL</a>) stock is diving more than 21% on <a href="https://www.nasdaq.com/press-release/leslies-inc-announces-preliminary-third-quarter-fiscal-2024-financial-results-and">preliminary earnings and guidance</a>.</li>



<li>Aptevo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/apvo-stock-quote/">APVO</a>) shares are rumbling over 13% after a massive rally yesterday.</li>



<li>Domino&rsquo;s Pizza (NYSE:<a href="https://investorplace.com/stock-quotes/dpz-stock-quote/">DPZ</a>) stock is sliding more than 13% with the release of its <a href="https://ir.dominos.com/static-files/68ecdbfc-bd1c-486a-a574-d6f54b7e5132">Q2 earnings report</a>.</li>



<li>CBL International (NASDAQ:<a href="https://investorplace.com/stock-quotes/banl-stock-quote/">BANL</a>) shares are taking an over 12% beating on Thursday morning as it retreats from a rally yesterday.</li>



<li>WiMi Hologram Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/wimi-stock-quote/">WIMI</a>) stock is dropping close to 12% after an unexpected rally yesterday.</li>



<li>Beyond Meat (NASDAQ:<a href="https://investorplace.com/stock-quotes/bynd-stock-quote/">BYND</a>) shares are falling more than 11% on <a href="https://www.wsj.com/articles/beyond-meat-engages-bondholders-for-restructuring-talks-7de6b8ae">restructuring talks with bondholders</a>.</li>



<li>American Rebel (NASDAQ:<a href="https://investorplace.com/stock-quotes/areb-stock-quote/">AREB</a>) stock is decreasing over 11% this morning after rallying on Wednesday.</li>



<li>Aditxt (NASDAQ:<a href="https://investorplace.com/stock-quotes/adtx-stock-quote/">ADTX</a>) shares are slipping more than 10% <a href="https://investorplace.com/2024/07/why-is-aditxt-adtx-stock-up-72-today/">following a rally yesterday</a>.</li>



<li>Stardust Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdst-stock-quote/">SDST</a>) stock is dipping over 10% <a href="https://investorplace.com/2024/07/stardust-power-sdst-stock-pops-140-days-after-debut-what-to-know/">after a surprise rally yesterday</a>.</li>



<li>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-18th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

XWELL announces $1.4M registered direct offering

XWELL (XWEL) has provided an announcement. XWELL, Inc. has recently struck a deal with institutional and accredited investors to sell over 650,000 ...

XWELL Capital Boost: New Share Deals and Investor Agreements

XWELL reports Q2 results

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
XWELL (NASDAQ:<a href="https://investorplace.com/stock-quotes/xwel-stock-quote/">XWEL</a>) just reported results for the second quarter of 2024.<ul><li>XWELL reported earnings per share of -48 cents.</li><li>The company reported revenue of $9.28 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/xwel-stock-earnings-xwell-for-q2-of-2024/">XWEL Stock Earnings: XWELL Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XWEL Stock Earnings: XWELL Reported Results for Q2 2024

An announcement from XWELL ( ($XWEL) ) is now available. XWELL Inc. has appointed Ezra Ernst as its new President and CEO, aiming to spur growth an...

XWELL Names Ezra Ernst as President for Strategic Growth

XWELL names Ezra Ernst as CEO

ADTX

APLM

APVO

AREB

BANL

BNOX

BYND

CHUY

LESL

ONCO

SDST

WIMI

XWEL

ZIMV

Press Releases

XWELL Opens New XpresSpa Location at Philadelphia International Airport

XWELL Announces Director Candidate Nomination Notice Submitted by CPC is Invalid

CPC Issues Letter to Fellow XWELL, Inc. Shareholders Revealing Intention Behind Recent Schedule 13D Filing & Lawsuit Against Entrenched Board of Directors

Comments

XWELL

Notizie

Ultime notizie per XWELL (NASDAQ:XWEL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO